These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23055177)

  • 1. Pathogenic relevance of anti-citrullinated vimentin antibodies: comment on the article by Montes et al.
    van der Woude D; Scherer HU; Huizinga TW; Toes RE
    Arthritis Rheum; 2013 Feb; 65(2):541-2. PubMed ID: 23055177
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: Pathogenic relevance of anti-citrullinated vimentin antibodies: comment on the article by Montes et al.
    Montes A; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
    Arthritis Rheum; 2013 Feb; 65(2):542. PubMed ID: 23055154
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis.
    Montes A; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
    Arthritis Rheum; 2012 Oct; 64(10):3102-10. PubMed ID: 22674012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis.
    Brink M; Hansson M; Mathsson L; Jakobsson PJ; Holmdahl R; Hallmans G; Stenlund H; Rönnelid J; Klareskog L; Rantapää-Dahlqvist S
    Arthritis Rheum; 2013 Apr; 65(4):899-910. PubMed ID: 23310951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis.
    Van Steendam K; Tilleman K; Deforce D
    Rheumatology (Oxford); 2011 May; 50(5):830-7. PubMed ID: 21278075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations and anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis: comment on the editorial by Levesque et al.
    Firestein GS
    Arthritis Rheum; 2010 Jan; 62(1):303-4. PubMed ID: 20039399
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
    Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
    Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of anti-cyclic citrullinated peptide and anti-Sa/citrullinated vimentin autoantibodies in rheumatoid arthritis.
    Rodríguez-Mahou M; López-Longo FJ; Sánchez-Ramón S; Estecha A; García-Segovia A; Rodríguez-Molina JJ; Carreño L; Fernández-Cruz E
    Arthritis Rheum; 2006 Aug; 55(4):657-61. PubMed ID: 16874789
    [No Abstract]   [Full Text] [Related]  

  • 10. An intriguing relationship between the immune response to citrullinated vimentin and the HLA shared epitope: comment on the article by Verpoort et al.
    Bell DA; Hill JA; Cairns E
    Arthritis Rheum; 2008 Oct; 58(10):3277; author reply 3277-8. PubMed ID: 18821677
    [No Abstract]   [Full Text] [Related]  

  • 11. Smoking, the HLA-DRB1 shared epitope and ACPA fine-specificity in Koreans with rheumatoid arthritis: evidence for more than one pathogenic pathway linking smoking to disease.
    Fisher BA; Bang SY; Chowdhury M; Lee HS; Kim JH; Charles P; Venables P; Bae SC
    Ann Rheum Dis; 2014 Apr; 73(4):741-7. PubMed ID: 23505239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence and diagnostic performances of IgA class antibodies to mutated citrullinated vimentin in rheumatoid arthritis.
    Sghiri R; Khalifa O; Bouajina E; Ben Haj Slama F; Baccouche K; Ben Fredj H; Gaha R; Boukadida J
    Joint Bone Spine; 2010 May; 77(3):279-80. PubMed ID: 20378382
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis.
    Al-Jarallah K; Shehab D; Al-Attiyah R; Al-Azmi W; Al-Fadli A; Zafar Haider M; Panaccione R; Ghosh S
    Inflamm Bowel Dis; 2012 Sep; 18(9):1655-62. PubMed ID: 22114016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis.
    Raza K; Mathsson L; Buckley CD; Filer A; Rönnelid J
    Ann Rheum Dis; 2010 Mar; 69(3):627-8. PubMed ID: 19846408
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.
    Vossenaar ER; Després N; Lapointe E; van der Heijden A; Lora M; Senshu T; van Venrooij WJ; Ménard HA
    Arthritis Res Ther; 2004; 6(2):R142-50. PubMed ID: 15059278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.